Clinical Trial of YH14618 in Patients With Degenerative Disc Disease
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Research Hypothesis:
There will be a greater proportion of VAS responders defined as those who achieve ≥ 50%
reduction from baseline in VAS for low back pain at week 12 following intradiscal injection
of YH14618 compared to placebo. Patients have been diagnosed as one or two symptomatic lumbar
degenerative disc disease defined as Pfirrmann grade 2 to 4 using MRI. Patients have suffered
from persistent low back pain with at least 3 months of conservative therapy and must have
low back pain measured by VAS≥4 cm and modified Oswestry disability index (mODI) ≥30% at the
baseline.